市场调查报告书
商品编码
1423644
2030 年强度调控放射治疗(IMRT) 市场预测:按放射类型、应用、最终用户和地区进行的全球分析Intensity Modulated Radiation Therapy Market Forecasts to 2030 - Global Analysis By Radiation Type (Proton Radiation, Electron Radiation, Photon Radiation and Other Radiation Types), Application, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球强度调控放射治疗(IMRT) 市场规模为 22 亿美元,预计预测期内复合年增长率为 6.8%,到 2030 年将达到 35 亿美元。
强度调控放射治疗(IMRT) (IMRT) 是一种精确放射治疗技术,可在多个角度调整放射束强度。这允许对癌组织进行高剂量照射,同时最大限度地减少对周围健康结构的暴露。与传统放射线治疗相比,IMRT 的精确度提高了治疗效果并减少了副作用。
根据美国癌症协会估计,2022年美国将新增190万癌症病例。
全球癌症盛行率不断上升
世界各地的癌症发病率持续飙升,增加了对先进和精确治疗方法的需求。 IMRT 能够提供目标剂量,同时最大限度地减少对周围健康组织的损害,已成为肿瘤学领域的关键技术。各种癌症的盛行率不断增加以及人口老化增加了对有效和客製化治疗方法的需求。这一趋势支持 IMRT 作为综合癌症治疗的关键参与者,将其定位为不断发展的癌症治疗领域的关键解决方案。
治疗费用高
IMRT 的先进技术涉及精确的放射治疗、专业设备和熟练的人员,因此治疗费用昂贵。这种财务负担可能会拖累医疗机构和患者,特别是在医疗预算有限或报销政策不佳的地区。由于成本考量可能会削弱人们对更具成本效益的治疗方法的兴趣,从而影响 IMRT 的市场占有率,因此这种威胁会加剧。
个人化医疗整合
根据个别患者特征(例如基因组成和肿瘤概况)定制治疗,可以提高 IMRT 的准确性和有效性。个人化方法可以优化治疗计划、最大限度地减少副作用并改善治疗结果。这种协同效应与医疗保健领域精准医疗的更广泛趋势一致,促进更多以患者为中心和有针对性的治疗方法。 IMRT 与个人化医疗无缝整合的能力不仅扩大了 IMRT 的范围,而且使其处于尖端肿瘤治疗的前沿,推动需求和市场成长。
部署复杂度
IMRT 技术复杂,需要医疗保健专业人员(包括放射肿瘤学家和医学物理学家)进行专门培训,这可能导致技术人员短缺。 IMRT 涉及的复杂规划和交付流程不仅需要先进的设备,还需要对治疗规划软体有细緻的了解。将 IMRT 整合到现有的医疗保健系统中需要大量的基础设施投资和继续教育倡议。此外,掌握 IMRT 技术的学习曲线可能会阻碍快速和广泛的普及,特别是在资源有限或医疗保健差距较大的地区。
COVID-19大流行对市场产生了重大影响。这场危机导致医疗保健服务中断并推迟了选择性手术,包括非紧急癌症治疗。与 COVID-19 相关的医疗保健资源的重新分配和优先排序使常规癌症治疗的医疗保健设施的可用性紧张,并影响了 IMRT 的采用。此外,疫情后的经济挑战和医疗保健预算限制可能会影响投资决策并减缓市场成长。儘管遇到这些挫折,随着医疗保健系统适应不断变化的大流行后形势,IMRT 在晚期癌症治疗中的重要性仍然是康復的驱动力。
乳癌领域预计在预测期内规模最大
乳癌领域预计将出现良好的成长。 IMRT 辐射束调节的精确性能够对乳房肿瘤进行针对性照射,同时最大限度地减少对周围健康组织的暴露。因此,与传统放射线治疗相比,治疗效果提高,副作用减少。全球乳癌发病率不断上升,以及人们对先进和精准治疗方法的日益偏好,推动了乳癌病例对 IMRT 的需求,这些治疗有助于改善接受乳癌放射线治疗的患者的治疗结果和生活品质。的背景。
预计医院业在预测期内复合年增长率最高。
预计医院业在预测期内复合年增长率最高。这些医疗机构投资了最先进的 IMRT 技术和基础设施,使患者能够接受先进的放射线治疗。医院与放射肿瘤科医师和技术人员合作,提供精准、个人化的 IMRT 治疗。 IMRT 在医院内的整合将增强癌症治疗能力,实现有针对性的治疗,并最大限度地减少副作用。医院作为主要相关人员,为 IMRT 在更广泛的医疗保健环境中的发展和可近性做出了重大贡献。
由于先进的医疗基础设施、高癌症发病率以及积极的研发活动,预计北美市场在预测期内将继续占据大部分市场占有率。该地区拥有完善的报销政策并注重创新,这有助于普及。此外,医疗保健专业人员和患者对 IMRT 益处的认识不断提高,也提高了市场占有率。主要市场参与企业和研究机构之间的合作进一步加强了北美的地位,并确保对 IMRT 解决方案的需求持续激增,以满足该地区不断变化的癌症治疗需求。我是。
亚太地区在香料朗姆酒市场中发挥关键作用,由于癌症发病率上升、医疗基础设施的进步以及对先进治疗方案的认识不断增强,亚太地区在预测期内的复合年增长率最高。预计这种情况将会发生。由于癌症治疗投资的增加,中国、印度和日本等国家处于这一扩张的前沿。该地区庞大的患者群,加上政府改善癌症治疗的努力,为 IMRT 的采用创造了肥沃的土壤。
According to Stratistics MRC, the Global Intensity Modulated Radiation Therapy Market is accounted for $2.2 billion in 2023 and is expected to reach $3.5 billion by 2030 growing at a CAGR of 6.8% during the forecast period. Intensity Modulated Radiation Therapy (IMRT) is a precise radiotherapy technique that adjusts radiation beam intensity across multiple angles. This allows targeted delivery of higher doses to cancerous tissue while minimizing exposure to surrounding healthy structures. IMRT's precision enhances treatment effectiveness and reduces side effects compared to conventional radiation therapy.
According to the American Cancer Society, in 2022, an estimated 1.9 million new cases of cancer were diagnosed in the U.S.
The rising prevalence of cancer worldwide
Cancer rates continue to surge worldwide, there is a heightened demand for advanced and precise treatment modalities. IMRT, with its ability to deliver targeted radiation doses while minimizing damage to surrounding healthy tissues, have emerged as a crucial technology in the oncology landscape. The rising prevalence of diverse cancer types, coupled with an aging population, underscores the need for effective and tailored therapies. This trend propels the adoption of IMRT as a key player in the comprehensive oncological care, positioning it as a vital solution in the evolving landscape of cancer treatment.
High treatment costs
IMRT's sophisticated technology, involving precise radiation delivery, specialized equipment, and skilled personnel, contributes to elevated treatment expenses. This financial burden may deter healthcare institutions and patients, particularly in regions with limited healthcare budgets or where reimbursement policies are insufficient. The threat intensifies as cost considerations may divert attention toward alternative, more cost-effective treatment options, impacting IMRT's market share.
Personalized medicine integration
Tailoring treatments to individual patient characteristics, such as genetic makeup and tumor profiles, enhances the precision and effectiveness of IMRT. Personalized approaches allow for optimized treatment plans, minimizing side effects and improving outcomes. This synergy aligns with the broader trend in healthcare towards precision medicine, fostering a more patient-centric and targeted therapeutic approach. The ability of IMRT to seamlessly integrate with personalized medicine not only expands its applicability but also positions it at the forefront of cutting-edge oncological care, driving demand and market growth.
Complexity of implementation
IMRT's intricate technology demands specialized training for healthcare professionals, including radiation oncologists and medical physicists, leading to a potential shortage of adequately skilled personnel. The sophisticated planning and delivery processes involved in IMRT require not only advanced equipment but also a nuanced understanding of treatment planning software. Integration of IMRT into existing healthcare systems necessitates substantial investments in infrastructure and continuous educational initiatives. Moreover, the learning curve for mastering IMRT techniques may hinder its swift and widespread adoption, particularly in regions with limited resources or healthcare disparities.
The COVID-19 pandemic significantly impacted the market. The crisis led to disruptions in healthcare services, delaying elective procedures, including non-urgent cancer treatments. Resource reallocation and prioritization of COVID-19-related care strained the availability of medical facilities for routine cancer therapies, affecting the adoption of IMRT. Moreover, economic challenges and healthcare budget constraints in the wake of the pandemic may have influenced investment decisions, potentially slowing down the market's growth. Despite these setbacks, the importance of IMRT in advanced cancer care continues to drive its recovery as healthcare systems adapt to the evolving post-pandemic landscape.
The breast cancer segment is expected to be the largest during the forecast period
The breast cancer segment is expected to have a lucrative growth. IMRT's precision in adjusting radiation beams allows for targeted delivery to breast tumors while minimizing exposure to surrounding healthy tissue. This results in enhanced treatment efficacy and reduced side effects compared to conventional radiation therapy. The demand for IMRT in breast cancer cases is driven by the rising incidence of breast cancer globally, coupled with the increasing preference for advanced and precise treatment modalities that contribute to improved outcomes and better quality of life for patients undergoing radiation therapy for breast cancer.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period. These healthcare institutions invest in state-of-the-art IMRT technology and infrastructure, ensuring access to advanced radiation therapies for patients. Hospitals collaborate with radiation oncologists and technologists to deliver precise and personalized IMRT treatments. The integration of IMRT within hospital settings enhances cancer care capabilities, allowing for targeted therapy delivery and minimizing side effects. As key stakeholders, hospitals contribute significantly to the growth and accessibility of IMRT in the broader healthcare landscape.
During the forecast period, it is expected that the North American market will continue to hold a majority of the market share, driven by advanced healthcare infrastructure, a high prevalence of cancer, and robust R&D activities. The region's well-established reimbursement policies and a strong focus on technological innovation contribute to widespread adoption. Moreover, increasing awareness about the benefits of IMRT among healthcare professionals and patients enhances its market presence. Collaboration between key market players and research institutions further solidifies North America's position, ensuring a continuous surge in demand for IMRT solutions to address the evolving needs of cancer treatment in the region.
The Asia Pacific region plays a significant role in the spice rum market and is projected to have the highest CAGR over the forecast period driven by increasing cancer prevalence, advancing healthcare infrastructure, and rising awareness of advanced treatment options. Countries like China, India, and Japan are at the forefront of this expansion, with growing investments in oncology care. The region's large patient pool, coupled with government initiatives to improve cancer treatment, creates a fertile ground for IMRT adoption.
Key players in the market
Some of the key players in Intensity Modulated Radiation Therapy market include Accuray Incorporated, Brainlab AG, Varian Medical Systems, Inc, Elekta AB, Hitachi, Ltd., IBA Worldwide, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, Raysearch Laboratories and Siemens Healthineers AG.
In October 2023, Siemens Healthineers AG Partnered with RefleXion X to develop AI-powered solutions for optimizing IMRT treatment plans.
In June 2023, Elekta AB. acquired Monaco, a leading treatment planning software for IMRT and other modalities.
In November 2022, Accuray unveiled a strategic collaboration with Limbus AI to bolster adaptive radiotherapy solutions. This partnership marked a significant milestone in expanding Accuray's product portfolio, showcasing the company's commitment to advancing cutting-edge technologies in the field of radiotherapy.